News articles about Vertex Pharmaceuticals (NASDAQ:VRTX) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news stories about the pharmaceutical company an impact score of 45.9798622788751 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
VRTX has been the topic of a number of research reports. HC Wainwright restated a “hold” rating and issued a $103.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 13th. Deutsche Bank initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $175.00 price target on the stock. Oppenheimer upped their price target on Vertex Pharmaceuticals from $175.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, January 4th. BidaskClub upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. Finally, Bank of America restated a “buy” rating and issued a $180.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twenty-five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $183.96.
Shares of Vertex Pharmaceuticals stock traded down $3.41 during trading hours on Friday, reaching $154.25. 1,446,291 shares of the company’s stock were exchanged, compared to its average volume of 1,381,664. Vertex Pharmaceuticals has a 52-week low of $111.32 and a 52-week high of $178.25. The firm has a market cap of $39,162.84, a PE ratio of 192.81, a P/E/G ratio of 2.20 and a beta of 1.49. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.08. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. The company had revenue of $651.63 million for the quarter, compared to analyst estimates of $592.49 million. During the same quarter in the prior year, the company posted $0.35 EPS. The business’s revenue for the quarter was up 42.1% compared to the same quarter last year. equities research analysts anticipate that Vertex Pharmaceuticals will post 1.7 EPS for the current year.
Vertex Pharmaceuticals declared that its Board of Directors has authorized a share repurchase program on Wednesday, January 31st that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the pharmaceutical company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.
In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 4,250 shares of the stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $159.00, for a total transaction of $675,750.00. Following the transaction, the executive vice president now owns 46,202 shares of the company’s stock, valued at approximately $7,346,118. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey M. Leiden sold 99,563 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $156.99, for a total value of $15,630,395.37. Following the transaction, the chief executive officer now directly owns 176,747 shares in the company, valued at approximately $27,747,511.53. The disclosure for this sale can be found here. In the last three months, insiders have sold 344,147 shares of company stock worth $55,123,669. Corporate insiders own 1.80% of the company’s stock.
WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/vertex-pharmaceuticals-vrtx-given-daily-media-impact-rating-of-0-23.html.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.